Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07135895 · ClinicalTrials.gov registry record · NA

The ArtixASCEND Study

A NA study of Acute Lower Limb Arterial Occlusion, sponsored by Inari Medical.

Recruiting
Registry status
NA
Development phase
250
Enrollment target
5
Study locations

NCT07135895 is a NA study of Acute Lower Limb Arterial Occlusion that is actively recruiting participants, run by Inari Medical. The registered enrollment target is 250 participants. The trial reports 5 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07135895, a NA study of Acute Lower Limb Arterial Occlusion, is actively recruiting participants, sponsored by Inari Medical.

RECRUITING
Registry status
NA
Development phase
250 participants
Enrollment target
5
Study locations

Study Summary

This study is a post-market, prospective, multicenter, single-arm study to evaluate the safety and effectiveness of the Artix Thrombectomy System in patients with acute lower extremity arterial occlusions.

Interventions

  • DEVICE Artix Thrombectomy System

Study Locations (5)

Connecticut

  • Yale University - New Haven

District of Columbia

  • MedStar Washington Hospital Center - Washington D.C.

North Carolina

  • Mission Memorial Hospital - Asheville

Oklahoma

  • Ascension St. John Jane Phillips Medical Center - Bartlesville

South Carolina

  • Grand Strand Medical Center - Myrtle Beach

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2026-01-07
Est. Completion 2029-10-01
Phase NA

Sponsor

Inari Medical

12 total trials

What the Registry Record Tells You About NCT07135895

The ClinicalTrials.gov registry entry for NCT07135895 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Inari Medical, which has 12 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acute Lower Limb Arterial Occlusion appearing as the primary indexed condition, and to 1 intervention - of which Artix Thrombectomy System is the first listed.

NCT07135895 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Connecticut, District of Columbia, North Carolina.

Frequently Asked Questions

What is clinical trial NCT07135895 about?

NCT07135895 is a clinical study titled "The ArtixASCEND Study". This study is a post-market, prospective, multicenter, single-arm study to evaluate the safety and effectiveness of the Artix Thrombectomy System in patients with acute lower extremity arterial occlusions.

What is the current status of trial NCT07135895?

This trial is currently recruiting. It is a NA study. The enrollment target is 250 participants. The study started on 2026-01-07. Estimated completion is 2029-10-01.

What conditions does trial NCT07135895 study?

This clinical trial studies the following conditions: Acute Lower Limb Arterial Occlusion.

What interventions are being tested in trial NCT07135895?

The interventions under investigation include: Artix Thrombectomy System (DEVICE).

Who is sponsoring clinical trial NCT07135895?

This trial is sponsored by Inari Medical, which has 12 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07135895 being conducted?

This trial has 5 study locations across Connecticut, District of Columbia, North Carolina, Oklahoma, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.